Nurix Therapeutics (NRIX) Cash from Financing Activities (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Cash from Financing Activities for 8 consecutive years, with $66000.0 the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash from Financing Activities rose 1000.0% year-over-year to $66000.0; the TTM figure through May 2026 stood at $257.2 million (up 3.81% YoY), while the FY2025 annual figure was $238.6 million, down 50.86% from the prior year.
• Cash from Financing Activities declined to $66000.0 in Q2 2026 per NRIX's latest filing, from $20.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $237.8 million in Q2 2024 and bottomed at -$135000.0 in Q4 2022.
• Historically, Cash from Financing Activities has averaged $48.0 million across 5 years, with a median of $1.5 million in 2022.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities tumbled 127.0% — and 2024, when it jumped 2864485.71%.
• Nurix Therapeutics' Cash from Financing Activities stood at -$135000.0 in 2022, then surged by 105.19% to $7000.0 in 2023, then surged by 2864485.71% to $200.5 million in 2024, then advanced by 17.7% to $236.0 million in 2025, then sank by 99.97% to $66000.0 in 2026.
• Business Quant data shows NRIX's Cash from Financing Activities at $66000.0 in Q2 2026, $20.0 million in Q1 2026, and $236.0 million in Q4 2025.